Presentation is loading. Please wait.

Presentation is loading. Please wait.

2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Atul Verma, MD, John A. Cairns, MD, L.

Published byLuke Rice Modified over 6 years ago

Similar presentations

Presentation on theme: "2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Atul Verma, MD, John A. Cairns, MD, L."— Presentation transcript:

1 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Atul Verma, MD, John A. Cairns, MD, L. Brent Mitchell, MD, Laurent Macle, MD, Ian G. Stiell, MD, David Gladstone, MD, Michael Sean McMurtry, MD, Stuart Connolly, MD, Jafna L. Cox, MD, Paul Dorian, MD, Noah Ivers, MD, Kori Leblanc, PharmD, Stanley Nattel, MD, Jeff S. Healey, MD  Canadian Journal of Cardiology  Volume 30, Issue 10, Pages (October 2014) DOI: /j.cjca Copyright © 2014 Canadian Cardiovascular Society Terms and Conditions

2 Figure 1 The simplified “CCS algorithm” for deciding which patients with atrial fibrillation (AF) or atrial flutter (AFL) should receive oral anticoagulation (OAC) therapy. * We suggest that a NOAC be used in preference to warfarin for non-valvular AF. † Might require lower dosing. ASA, acetylsalicylic acid; CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; CHADS2, Congestive Heart Failure, Hypertension, Age, Diabetes, Stroke/Transient Ischemic Attack; eGFR, estimated glomerular filtration rate; INR, international normalized ratio; NOAC, novel oral anticoagulant; NSAID, nonsteroidal anti-inflammatory drug; TIA, transient ischemic attack. Canadian Journal of Cardiology  , DOI: ( /j.cjca ) Copyright © 2014 Canadian Cardiovascular Society Terms and Conditions

3 Figure 2 Decision algorithm for management of oral anticoagulation (OAC) therapy for patients who present to the emergency department (ED) with recent-onset atrial fibrillation (AF) requiring rate control or cardioversion (CV) in the ED. † Immediate OAC = a dose of OAC should be given just before cardioversion; either a novel direct oral anticoagulant (NOAC) or a dose of heparin or low molecular weight heparin with bridging to warfarin if a NOAC is contraindicated. ASA, acetylsalicylic acid; CAD, coronary artery disease; CHADS2, Congestive Heart Failure, Hypertension, Age, Diabetes, Stroke/Transient Ischemic Attack; TIA, transient ischemic attack. Canadian Journal of Cardiology  , DOI: ( /j.cjca ) Copyright © 2014 Canadian Cardiovascular Society Terms and Conditions

4 Figure 3 Approach to rate and/or rhythm control of atrial fibrillation (AF) in patients presenting with symptomatic AF. QOL, quality of life. Canadian Journal of Cardiology  , DOI: ( /j.cjca ) Copyright © 2014 Canadian Cardiovascular Society Terms and Conditions

Download ppt "2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Atul Verma, MD, John A. Cairns, MD, L."

Similar presentations

Emergency/Urgent Referral* (3) -Pt acutely unwell with palpitations -Pt with haemodyanically unstable acute onset AF -2 nd /3 rd heart block -Exercise.

Emergency/Urgent Referral* (3) -Pt acutely unwell with palpitations -Pt with haemodyanically unstable acute onset AF -2 nd /3 rd heart block -Exercise.
CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation 

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation 
Systemic Implementation Strategies to Improve Hypertension: The Kaiser Permanente Southern California Experience  John J. Sim, MD, Joel Handler, MD, Steven.

Systemic Implementation Strategies to Improve Hypertension: The Kaiser Permanente Southern California Experience  John J. Sim, MD, Joel Handler, MD, Steven.
Kiran Sidhu, MD, FRCPC, Anthony Tang, MD, FRCPC 

Kiran Sidhu, MD, FRCPC, Anthony Tang, MD, FRCPC 
Aligning Health Care Policy With Evidence-Based Medicine: The Case for Funding Direct Oral Anticoagulants in Atrial Fibrillation  James A. Stone, MD,

Aligning Health Care Policy With Evidence-Based Medicine: The Case for Funding Direct Oral Anticoagulants in Atrial Fibrillation  James A. Stone, MD,
Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy  Jean-François Tanguay, MD, CSPQ, FRCPC, FACC,

Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy  Jean-François Tanguay, MD, CSPQ, FRCPC, FACC,
2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation  Chern-En Chiang, Tsu-Juey.

2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation  Chern-En Chiang, Tsu-Juey.
Antithrombotic Therapy in Atrial Fibrillation

Antithrombotic Therapy in Atrial Fibrillation
171 The risk stratification and stroke prevention therapy care gap in canadian atrial fibrillation patients: Insights from the Facilitating Review and.

171 The risk stratification and stroke prevention therapy care gap in canadian atrial fibrillation patients: Insights from the Facilitating Review and.
Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention 

Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention 
Frontiers of anticoagulation therapy for atrial fibrillation

Frontiers of anticoagulation therapy for atrial fibrillation
The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have Evidence  David D. Waters, MD, Sripal Bangalore, MD,

The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have Evidence  David D. Waters, MD, Sripal Bangalore, MD,
The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines  Laurent Macle, MD,

The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines  Laurent Macle, MD,
Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Qual Outcomes
Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal  Gregory.

Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal  Gregory.
Volume 14, Issue 6, Pages (June 2017)

Volume 14, Issue 6, Pages (June 2017)
Role of the CHADS2 Score in Acute Coronary Syndromes

Role of the CHADS2 Score in Acute Coronary Syndromes
CHADS2 Score Predicts Postoperative Atrial Fibrillation in Patients Undergoing Elective Pulmonary Lobectomy  Svetlana Kotova, MD, Mansen Wang, PhD, Katie.

CHADS2 Score Predicts Postoperative Atrial Fibrillation in Patients Undergoing Elective Pulmonary Lobectomy  Svetlana Kotova, MD, Mansen Wang, PhD, Katie.
Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Implementation  Ratika Parkash, MD, MSc, François Philippon,

Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Implementation  Ratika Parkash, MD, MSc, François Philippon,
2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Laurent Macle, MD, John Cairns, MD, Kori.

2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Laurent Macle, MD, John Cairns, MD, Kori.

Similar presentations

Ads by Google